MAPT and Alzheimer disease: The aim of this longitudinal study was to investigate the associations between changes in tau PET with imaging biomarkers of neuronal injury (i.e., atrophy and CBF) in a cohort comprising i) amyloid negative (Aβ−) cognitively normal (CN) individuals, and ii) amyloid positive (Aβ+) CN and cognitively impaired (CI) (AD-phenotype) individuals.